MD III - Spruce Biosciences Chief Officer
| SPRB Stock | USD 0.55 0.02 3.77% |
Insider
MD III is Chief Officer of Spruce Biosciences
| Age | 54 |
| Address | 611 Gateway Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 415 655 4168 |
| Web | https://www.sprucebiosciences.com |
Spruce Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.3035) % which means that it has lost $0.3035 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5755) %, meaning that it created substantial loss on money invested by shareholders. Spruce Biosciences' management efficiency ratios could be used to measure how well Spruce Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 27, 2024, Return On Tangible Assets is expected to decline to -0.48. In addition to that, Return On Capital Employed is expected to decline to -0.69. As of November 27, 2024, Total Assets is expected to decline to about 89.5 M. In addition to that, Net Tangible Assets is expected to decline to about 61.8 MSimilar Executives
| Showing other executives | INSIDER Age | ||
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| MSc MBA | Inozyme Pharma | 52 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Arthur Taveras | X4 Pharmaceuticals | 60 | |
| Eric MD | Acumen Pharmaceuticals | 69 | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Murray MD | X4 Pharmaceuticals | 63 | |
| Demetrios MD | Inozyme Pharma | N/A | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Mary DiBiase | X4 Pharmaceuticals | 63 | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Jeffrey Bornstein | Eledon Pharmaceuticals | N/A | |
| Keith MD | X4 Pharmaceuticals | 53 | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Gregory Flesher | Eledon Pharmaceuticals | 54 | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| MA MS | Inozyme Pharma | N/A | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| MBA MBA | Inozyme Pharma | 65 | |
| Marine Popoff | Hookipa Pharma | N/A | |
Management Performance
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.3 |
Spruce Biosciences Leadership Team
Elected by the shareholders, the Spruce Biosciences' board of directors comprises two types of representatives: Spruce Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spruce. The board's role is to monitor Spruce Biosciences' management team and ensure that shareholders' interests are well served. Spruce Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spruce Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Pres CFO | ||
| MD III, Chief Officer | ||
| Libbie MBA, Chief Officer | ||
| P Ramtin, Senior Operations | ||
| Heidi MPH, Senior Quality | ||
| Michael Grey, Executive Chairman | ||
| MPH MD, CEO Director |
Spruce Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spruce Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (15.63) % | ||||
| Current Valuation | (34.94 M) | ||||
| Shares Outstanding | 41.3 M | ||||
| Shares Owned By Insiders | 10.50 % | ||||
| Shares Owned By Institutions | 41.43 % | ||||
| Number Of Shares Shorted | 232.77 K | ||||
| Price To Book | 0.42 X | ||||
| Price To Sales | 3.08 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spruce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spruce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spruce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spruce Biosciences Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spruce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share 0.173 | Quarterly Revenue Growth (0.80) | Return On Assets (0.30) | Return On Equity (0.58) |
The market value of Spruce Biosciences is measured differently than its book value, which is the value of Spruce that is recorded on the company's balance sheet. Investors also form their own opinion of Spruce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Spruce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spruce Biosciences' market value can be influenced by many factors that don't directly affect Spruce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spruce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.